Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Sterling Capital Management LLC

Sterling Capital Management LLC lowered its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 47.5% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 450,992 shares of the company’s stock after selling 408,196 shares during the quarter. Sterling Capital Management LLC’s holdings in Teva Pharmaceutical Industries were worth $13,584,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in TEVA. AQR Capital Management LLC raised its position in shares of Teva Pharmaceutical Industries by 24.6% during the first quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock worth $368,000 after purchasing an additional 4,732 shares during the period. Focus Partners Wealth grew its position in Teva Pharmaceutical Industries by 4.5% during the first quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after purchasing an additional 1,739 shares in the last quarter. Franklin Resources Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth $255,000. Flow Traders U.S. LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter worth about $238,000. Finally, Cerity Partners LLC raised its position in Teva Pharmaceutical Industries by 2.9% during the second quarter. Cerity Partners LLC now owns 45,837 shares of the company’s stock valued at $768,000 after acquiring an additional 1,291 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on TEVA. Piper Sandler reaffirmed an “overweight” rating and issued a $42.00 price target (up from $41.00) on shares of Teva Pharmaceutical Industries in a research report on Thursday, April 30th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. JPMorgan Chase & Co. upped their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Bank of America upped their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, April 9th. Finally, Barclays increased their price target on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and an average target price of $41.78.

Insider Buying and Selling

In other news, EVP Christine Fox sold 21,258 shares of the stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $35.31, for a total transaction of $750,619.98. Following the completion of the sale, the executive vice president owned 63,647 shares of the company’s stock, valued at $2,247,375.57. This represents a 25.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Eliyahu Sharon Kalif sold 153,251 shares of the stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $35.61, for a total value of $5,457,268.11. Following the transaction, the executive vice president owned 172,184 shares of the company’s stock, valued at approximately $6,131,472.24. This trade represents a 47.09% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 465,931 shares of company stock valued at $16,332,989. 0.54% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Stock Down 1.1%

Teva Pharmaceutical Industries stock opened at $33.24 on Friday. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $14.99 and a fifty-two week high of $37.35. The firm has a market capitalization of $38.22 billion, a price-to-earnings ratio of 24.99, a PEG ratio of 4.11 and a beta of 0.84. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. The company’s 50 day simple moving average is $33.73 and its 200 day simple moving average is $32.39.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The business had revenue of $3.98 billion during the quarter. As a group, sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.97 EPS for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.